HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma

Oncology Reports

Volumn 18, Issue 6, 2007, Pages 1463-1468

  Komohara, Yoshihiro ^a,d   Harada, Mamoru ^a,b   Ishihara, Yuki ^a   Suekane, Shigetaka ^a   Noguchi, Masanori ^a   Yamada, Akira ^a,c   Matsuoka, Kei ^a   Itoh, Kyogo ^a,c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

HLA A24; HLA G; Immunotherapy; Peptide; Renal cell carcinoma

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-G ANTIGEN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; KIDNEY NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 38449117970     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.6.1463     Document Type: Article

References (30)

1. Selli C, Hinshaw WM, Woodard BH and Paulson DF: Stratification of risk factors in renal cell carcinoma. Cancer 52: 899-903, 1983. (Pubitemid 13037658)
2. Yagoda A, Abi-Rached B and Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-93. Semin Oncol 22: 42-60, 1995.
3. Motzer RJ: Renal cell carcinoma: a priority malignancy for development and study of novel therapies. J Clin Oncol 21: 1193-1194, 2003.
4. Novellino L, Castelli C and Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54: 187-207, 2005. (Pubitemid 40174238)
5. Yamada A, Kawano K, Koga M, Matsumoto T and Itoh K: Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61: 6459-6466, 2001. (Pubitemid 32783252)
6. Itoh K and Yamada A: Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 97: 970-976, 2006. (Pubitemid 44322541)
7. Komohara Y, Harada M, Arima Y, et al: Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. Int J Oncol 29: 1555-1560, 2006.
8. Kawagoe N, Shintaku I, Yutani S, et al: Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164: 2090-2095, 2000.
9. Miyagi Y, Imai N, Sasatomi T, et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7: 3950-3962, 2001. (Pubitemid 34044613)
10. Komohara Y, Harada M, Arima Y, et al: Identification of target antigens in specific immunotherapy for renal cell carcinoma. J Urol 177: 1157-1162, 2007. (Pubitemid 46216367)
11. Kim R, Emi M, Tanabe K and Arihiko K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66: 5527-5536, 2006. (Pubitemid 43927099)
12. Pazmany L, Mandelboim O, Vales-Gomez M, et al: Human leukocyte antigen-G and its recognition by natural killer cells. J Reprod Immunol 43: 127-137,1999. (Pubitemid 29349677)
13. Le Gal FA, Titeau B, Sedilik C, et al: HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11: 1351-1356, 1999.
14. Rouas-Freiss N, Moreau P, Ferrone S and Carosella ED: HLA-G protein in cancer: Do they provide tumor cells with an escape mechanism? Cancer Res 65: 10139-10144. 2005. (Pubitemid 41743699)
15. Onno M, Guillaudeux T, Amiot L, et al: The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol 41: 79-86, 1994. (Pubitemid 24319055)
16. Ibrahim EC, Guerra N, Lacombe MJT, et al: Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61: 6838-6845, 2001. (Pubitemid 32896508)
17. Urosevic M, Kurrer MO, Kamarashev J, et al: Human leukocyte antigen G up-regulation in lung cancer associated with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159: 817-824, 2001. (Pubitemid 32847172)
18. Kleinberg L, Florenes VA, Skrede M, et al: Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449: 31-39, 2006. (Pubitemid 43988363)
19. Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG and Xie X: Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci 78: 2643-2649, 2006.
20. El-Chennawi FA, Auf FA, El-Diasty AM, et al: Expression of HLA-G in cancer bladder. Egypt J Immunol 12: 57-64, 2005.
21. BuKur J, Rebmann V, Gross-Wilde H, et al: Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63: 4107-4111, 2003.
22. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K and Harada M: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11: 6933-6943, 2005. (Pubitemid 41428751)
23. Takiguchi M, Matsuda T, Tomiyama H and Miwa K: Analysis of three HLA-A*3303 binding peptide anchors using an HLA-A*3303 stabilization assay. Tissue Antigens 55: 296-302, 2000. (Pubitemid 30237397)
24. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228, 2002. (Pubitemid 34493956)
25. Esquivel F, Yewdell J and Bennink J: RMA/S cells present endogeneously synthesized cytosolic proteins to class I restricted cytotoxic T lymphocytes. J Exp Med 175: 163-168, 1992.
26. Malmberg KJ, Levitsky V, Norell H, et al: IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via CD94/NKG2A-dependent mechanism. J Clin Invest 110: 1515-1523, 2002. (Pubitemid 35396922)
27. Idenoue S, Hirohashi Y, Torigoe T, et al: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11: 1474-1482, 2005. (Pubitemid 40315229)
28. Wang M, Johansen B, Nissen MH, et al: Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors. Cancer Lett 251: 86-95, 2007. (Pubitemid 46589771)
29. Tanaka K, Harashima N, Niiya F, et al: Serine proteinase inhibitor 9 can be recognized by cytotoxici T lymphocytes of epithelial cancer patients. Jpn J Cancer Res 93: 198-208, 2002. (Pubitemid 34223764)
30. Sasada T, Takedatsu H, Azuma K, et al: Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 64: 2882-2888, 2004. (Pubitemid 38500629)